10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of $1.61 billion. The enterprise value is $1.30 billion.
Important Dates
The last earnings date was Tuesday, October 29, 2024, after market close.
| Earnings Date | Oct 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
10x Genomics has 121.05 million shares outstanding. The number of shares has increased by 3.00% in one year.
| Current Share Class | 107.00M |
| Shares Outstanding | 121.05M |
| Shares Change (YoY) | +3.00% |
| Shares Change (QoQ) | +0.55% |
| Owned by Insiders (%) | 8.37% |
| Owned by Institutions (%) | 89.66% |
| Float | 104.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.53 |
| Forward PS | 2.26 |
| PB Ratio | 2.23 |
| P/TBV Ratio | 2.30 |
| P/FCF Ratio | 61.91 |
| P/OCF Ratio | 41.17 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 49.92 |
Financial Position
The company has a current ratio of 4.90, with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.90 |
| Quick Ratio | 3.97 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | 3.30 |
| Interest Coverage | -14,301.25 |
Financial Efficiency
Return on equity (ROE) is -24.87% and return on invested capital (ROIC) is -12.98%.
| Return on Equity (ROE) | -24.87% |
| Return on Assets (ROA) | -11.37% |
| Return on Capital (ROIC) | -12.98% |
| Revenue Per Employee | $500,193 |
| Profits Per Employee | -$144,997 |
| Employee Count | 1,259 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 2.40 |
Taxes
In the past 12 months, 10x Genomics has paid $6.63 million in taxes.
| Income Tax | 6.63M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.45% in the last 52 weeks. The beta is 1.87, so 10x Genomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.87 |
| 52-Week Price Change | -69.45% |
| 50-Day Moving Average | 17.73 |
| 200-Day Moving Average | 25.40 |
| Relative Strength Index (RSI) | 30.78 |
| Average Volume (20 Days) | 1,976,552 |
Short Selling Information
The latest short interest is 7.61 million, so 6.28% of the outstanding shares have been sold short.
| Short Interest | 7.61M |
| Short Previous Month | 7.65M |
| Short % of Shares Out | 6.28% |
| Short % of Float | 7.25% |
| Short Ratio (days to cover) | 3.26 |
Income Statement
In the last 12 months, 10x Genomics had revenue of $629.74 million and -$182.55 million in losses. Loss per share was -$1.53.
| Revenue | 629.74M |
| Gross Profit | 419.61M |
| Operating Income | -171.62M |
| Pretax Income | -233.22M |
| Net Income | -182.55M |
| EBITDA | -134.77M |
| EBIT | -171.62M |
| Loss Per Share | -$1.53 |
Full Income StatementBalance Sheet
The company has $398.16 million in cash and $85.88 million in debt, giving a net cash position of $312.28 million or $2.58 per share.
| Cash & Cash Equivalents | 398.16M |
| Total Debt | 85.88M |
| Net Cash | 312.28M |
| Net Cash Per Share | $2.58 |
| Equity (Book Value) | 722.80M |
| Book Value Per Share | 5.97 |
| Working Capital | 472.66M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $39.17 million and capital expenditures -$13.13 million, giving a free cash flow of $26.04 million.
| Operating Cash Flow | 39.17M |
| Capital Expenditures | -13.13M |
| Free Cash Flow | 26.04M |
| FCF Per Share | $0.22 |
Full Cash Flow StatementMargins
Gross margin is 66.63%, with operating and profit margins of -27.25% and -28.99%.
| Gross Margin | 66.63% |
| Operating Margin | -27.25% |
| Pretax Margin | -27.93% |
| Profit Margin | -28.99% |
| EBITDA Margin | -21.40% |
| EBIT Margin | -27.25% |
| FCF Margin | -5.10% |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.00% |
| Shareholder Yield | -3.00% |
| Earnings Yield | -11.32% |
| FCF Yield | 1.62% |
Dividend DetailsAnalyst Forecast
The average price target for 10x Genomics is $25.14, which is 88.60% higher than the current price. The consensus rating is "Buy".
| Price Target | $25.14 |
| Price Target Difference | 88.60% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 12.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 9.65 and a Piotroski F-Score of 3.
| Altman Z-Score | 9.65 |
| Piotroski F-Score | 3 |